Identification of serum CCL15 in hepatocellular carcinoma

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 99-106

  Li, Y ^a   Wu, J ^a   Zhang, W ^a   Zhang, N ^a,b   Guo, H ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

biomarker; CCL15; HCC; invasion; migration

Indexed keywords

CHEMOKINE; CHEMOKINE CCL15; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINES, CC; FEMALE; HUMANS; LIVER NEOPLASMS; MACROPHAGE INFLAMMATORY PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 84872590915     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.494     Document Type: Article

References (29)

1. Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG (2002) Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1(12): 947-955.
2. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA (2007) Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 104(4): 1307-1312.
3. Blanc JF, Lalanne C, Plomion C, Schmitter JM, Bathany K, Gion JM, Bioulac-Sage P, Balabaud C, Bonneu M, Rosenbaum J (2005) Proteomic analysis of differentially expressed proteins in hepatocellular carcinoma developed in patients with chronic viral hepatitis C. Proteomics 5(14): 3778-3789.
4. Brown MF, Bahnck KB, Blumberg LC, Brissette WH, Burrell SA, Driscoll JP, Fedeles F, Fisher MB, Foti RS, Gladue RP, Guzman-Martinez A, Hayward MM, Lira PD, Lillie BM, Lu Y, Lundquist GD, McElroy EB, McGlynn MA, Paradis TJ, Poss CS, Roache JH, Shavnya A, Shepard RM, Trevena KA, Tylaska LA (2007) Piperazinyl CCR1 antagonists-optimization of human liver microsome stability. Bioorg Med Chem Lett 17(11): 3109-3112.
5. Carloni V, Romanelli RG, Mercurio AM, Pinzani M, Laffi G, Cotrozzi G, Gentilini P (1998) Knockout of alpha6 beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells. Gastroenterology 115(2): 433-442.
6. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K (2002) Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62(Suppl 1): 57-63.
7. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Palareti G, Gozzetti G (1995) The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. Liver Transpl Surg 1(4): 249-255.
8. Hu Y, Zhang S, Yu J, Liu J, Zheng S (2005) SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. Breast 14(4): 250-255.
9. Hwang J, Kim CW, Son KN, Han KY, Lee KH, Kleinman HK, Ko J, Na DS, Kwon BS, Gho YS, Kim J (2004) Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett 570(1-3): 47-51.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
11. Jiang J, Wu C, Shen Y, Xu B, Zheng X, Li X, Xu N (2011) Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma. Anticancer Res 31(2): 687-691.
12. Johnson PJ (2001) The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5(1): 145-159.
13. Kwon SH, Ju SA, Kang JH, Kim CS, Yoo HM, Yu R (2008) Chemokine Lkn-1/CCL15 enhances matrix metalloproteinase-9 release from human macrophages and macrophage-derived foam cells. Nutr Res Pract 2(2): 134-137.
14. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD (2005) Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51(4): 695-707.
15. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP (2006) Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6(9): 2865-2873.
16. Lim MS, Elenitoba-Johnson KS (2004) Proteomics in pathology research. Lab Invest 84(10): 1227-1244.
17. Marrero JA, Lok AS (2004) Newer markers for hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1): S113-S119.
18. Nomiyama H, Hieshima K, Nakayama T, Sakaguchi T, Fujisawa R, Tanase S, Nishiura H, Matsuno K, Takamori H, Tabira Y, Yamamoto T, Miura R, Yoshie O (2001) Human CC chemokine liver-expressed chemokine/CCL16 is a functional ligand for CCR1, CCR2 and CCR5, and constitutively expressed by hepatocytes. Int Immunol 13(8): 1021-1029.
19. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P (2005) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41(1): 40-47.
20. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306): 572-577.
21. Richter R, Bistrian R, Escher S, Forssmann WG, Vakili J, Henschler R, Spodsberg N, Frimpong-Boateng A, Forssmann U (2005) Quantum proteolytic activation of chemokine CCL15 by neutrophil granulocytes modulates mononuclear cell adhesiveness. J Immunol 175(3): 1599-1608.
22. Rocken C, Ebert MP, Roessner A (2004) Proteomics in pathology, research and practice. Pathol Res Pract 200(2): 69-82.
23. Seow TK, Ong SE, Liang RC, Ren EC, Chan L, Ou K, Chung MC (2000) Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry. Electrophoresis 21(9): 1787-1813.
24. Sheng S, Chen D, Van Eyk JE (2006) Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. Mol Cell Proteomics 5(1): 26-34.
25. Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y (1998) Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma. Hepatogastroenterology 45(23): 1737-1741.
26. Sun R, Gao P, Chen L, Ma D, Wang J, Oppenheim JJ, Zhang N (2005) Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. Cancer Res 65(4): 1433-1441.
27. Ward DG, Cheng Y, N'Kontchou G, Thar TT, Barget N, Wei W, Billingham LJ, Martin A, Beaugrand M, Johnson PJ (2006) Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer 94(2): 287-292.
28. Witjes CD, de Man RA, Eskens FA, Dwarkasing RS, Zondervan PE, Verhoef C, Ijzermans JN (2010) [Hepatocellular carcinoma: the significance of cirrhosis for treatment and prognosis-retrospective study]. Ned Tijdschr Geneeskd 154: A1747.
29. Zhang Z, Bast Jr. RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW (2004) Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64(16): 5882-5890.